Share this story:

Ventripoint To Resume Trading at the Market Opening Friday, September 25, 2020

Toronto, Ontario – TheNewswire - September 23, 2020- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) is pleased to announce that it has been advised by the TSXV Exchange that the Company’s shares will resume trading at the opening of the market on Friday, September 25, 2020.

“We are all so excited that Ventripoint starts trading on Friday.  It has been a long, thorough process to re-structure the Company with major advances in our products and processes,” states Dr. George Adams, Executive Chairman of Ventripoint. “The Company is well positioned for growth.”

 “We want to thank the many shareholders who have sent us encouragement during this period of uncertainty and need to thank the Ventripoint team, who used their time to significantly improve our product offerings and exhaustively respond in detail to the marketplace’s need for better cardiac analytics,” continued Dr. Adams.

The urgency to better understand the damaging effects of COVID-19 on the heart has significantly elevated the profile of our products amongst the cardiovascular community. Now we can deploy our full team to close the sales established with tier one prospects and continue to penetrate the ever-increasing need for accurate, clear and economic imaging of all quadrants of the heart.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Mr. Peter Weichler, Director



Mr. Clay Chase


Phone: 858-456-7300

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.